Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study

References

• Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol. 2014;25(12):2304–2313. doi:10.1093/annonc/mdu480.
   PubMed Web of Science ®Google Scholar
• Chicard M, Colmet-Daage L, Clement N, et al. Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma. Clin Cancer Res. 2018;24(4):939–949. doi:10.1158/1078-0432.CCR-17-1586.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi:10.1056/NEJMoa1113205.
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6(5):479–491. doi:10.1158/2159-8290.CD-15-1483.
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–1765. doi:10.1056/NEJMra1706174.
   PubMed Web of Science ®Google Scholar
• Stewart CM, Kothari PD, Mouliere F, et al. The value of cell-free DNA for molecular pathology. J Pathol. 2018;244(5):616–627. doi:10.1002/path.5048.
   PubMed Web of Science ®Google Scholar
• Iwama E, Sakai K, Azuma K, et al. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Ann Oncol. 2017;28(1):136–141. doi:10.1093/annonc/mdw531.
   PubMed Web of Science ®Google Scholar
• Gale D, Lawson ARJ, Howarth K, et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS One. 2018;13(3):e0194630. doi:10.1371/journal.pone.0194630.
   PubMed Web of Science ®Google Scholar
• Kim ST, Lee WS, Lanman RB, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget. 2015;6(37):40360–40369. doi:10.18632/oncotarget.5465.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209. doi:10.1056/NEJMoa1213261.
   PubMed Web of Science ®Google Scholar
• Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008–42018. doi:10.18632/oncotarget.5788.
   PubMedGoogle Scholar
• Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20(6):1698–1705. doi:10.1158/1078-0432.CCR-13-2482.
   PubMed Web of Science ®Google Scholar
• Stankunaite R, George SL, Gallagher L, et al. Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. Eur J Cancer. 2022;162:209–220. doi:10.1016/j.ejca.2021.09.042.
   PubMed Web of Science ®Google Scholar
• Abbou SD, Shulman DS, DuBois SG, Crompton BD. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatr Blood Cancer. 2019;66(5):e27595. doi:10.1002/pbc.27595.
   PubMed Web of Science ®Google Scholar
• Klega K, Imamovic-Tuco A, Ha G, et al. Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors. J Clin Oncol Precis Oncol. 2018;2018(2):1–13. doi:10.1200/PO.17.00285. doi:10.1200/PO.17.00285.
   Google Scholar
• Madanat-Harjuoja LM, Renfro LA, Klega K, et al. Circulating tumor DNA as a biomarker in patients with stage III and IV Wilms tumor: analysis from a children’s oncology group trial, AREN0533. J Clin Oncol. 2022;40(26):3047–3056. doi:10.1200/JCO.22.00098.
   PubMed Web of Science ®Google Scholar
• Ortiz MV. Leveraging circulating tumor DNA to optimize the initial management of childhood renal tumors. J Clin Oncol. 2022;40(26):3006–3010. doi:10.1200/JCO.22.00820.
   PubMed Web of Science ®Google Scholar
• Ueno-Yokohata H, Okita H, Nakasato K, et al. Preoperative diagnosis of clear cell sarcoma of the kidney by detection of BCOR internal tandem duplication in circulating tumor DNA. Genes Chromosomes Cancer. 2018;57(10):525–529. doi:10.1002/gcc.22648.
   PubMed Web of Science ®Google Scholar
• Roy A, Kumar V, Zorman B, et al. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nat Commun. 2015;6(Journal Article):8891. doi:10.1038/ncomms9891.
   PubMedGoogle Scholar
• Shulman DS, Klega K, Imamovic-Tuco A, et al. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group. Br J Cancer. 2018;119(5):615–621. doi:10.1038/s41416-018-0212-9.
   PubMed Web of Science ®Google Scholar
• van Zogchel LMJ, Lak NSM, Verhagen OJHM, et al. Novel circulating hypermethylated RASSF1A ddPCR for liquid biopsies in patients with pediatric solid tumors. J Clin Oncol Precis Oncol. 2021;5(5):1738–1748. doi:10.1200/PO.21.00130.
   Google Scholar
• Abbou S, Klega K, Tsuji J, et al. Circulating tumor DNA is prognostic in intermediate-risk rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol. 2023; 41(13):2382–2393. doi:10.1200/JCO.22.00409.
   PubMed Web of Science ®Google Scholar
• Doculara L, Trahair TN, Bayat N, Lock RB. Circulating tumor DNA in pediatric cancer. Front Mol Biosci. 2022;9:885597. doi:10.3389/fmolb.2022.885597.
   PubMed Web of Science ®Google Scholar
• Amendola LM, Berg JS, Horowitz CR, et al. The clinical sequencing evidence-generating research consortium: Integrating genomic sequencing in diverse and medically underserved populations. Am J Hum Genet. 2018;103(3):319–327. doi:10.1016/j.ajhg.2018.08.007.
   PubMed Web of Science ®Google Scholar
• CSER. https://cser-consortium.org.
   Google Scholar
• Mangum R, Reuther J, Bertrand KC, et al. Durable response to larotrectinib in a child with histologic diagnosis of recurrent disseminated ependymoma discovered to harbor an NTRK2 fusion: the impact of integrated genomic profiling. J Clin Oncol Precis Oncol. 2021;5(5):1221–1227. doi:10.1200/PO.20.00375.
   Google Scholar
• Wollison BM, Thai E, Mckinney A, et al. Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients. PLoS One. 2017;12(12):e0188835. doi:10.1371/journal.pone.0188835.
   PubMed Web of Science ®Google Scholar
• McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the ensembl API and SNP effect predictor. Bioinformatics. 2010;26(16):2069–2070. doi:10.1093/bioinformatics/btq330.
   PubMed Web of Science ®Google Scholar
• Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443. doi:10.1038/s41586-020-2308-7.
   PubMed Web of Science ®Google Scholar
• Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi:10.1038/nature15393.
   PubMed Web of Science ®Google Scholar
• Rossi G, Mu Z, Rademaker AW, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res. 2018;24(3):560–568. doi:10.1158/1078-0432.CCR-17-2092.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ju S, Wang X, Cong H. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Clin Exp Med. 2019;19(3):271–279. doi:10.1007/s10238-019-00563-w.
   PubMed Web of Science ®Google Scholar
• Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: a comprehensive review. Clin Genet. 2019;95(6):643–660. doi:10.1111/cge.13514.
   PubMed Web of Science ®Google Scholar
• Kukita Y, Uchida J, Oba S, et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One. 2013;8(11):e81468. doi:10.1371/journal.pone.0081468.
   PubMed Web of Science ®Google Scholar
• Li X, Ren R, Ren S, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. Transl Oncol. 2014;7(3):341–348. doi:10.1016/j.tranon.2014.04.006.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345–1353. doi:10.1097/JTO.0000000000000263.
   PubMed Web of Science ®Google Scholar
• Petit J, Carroll G, Gould T, Pockney P, Dun M, Scott RJ. Cell-free DNA as a diagnostic blood-based biomarker for colorectal cancer: a systematic review. J Surg Res. 2019;236:184–197. doi:10.1016/j.jss.2018.11.029.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yang T, Wu Q, et al. Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: a meta-analysis. Cancer Med. 2020;9(16):5699–5707. doi:10.1002/cam4.3276.
   PubMed Web of Science ®Google Scholar
• Barris DM, Weiner SB, Dubin RA, et al. Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget. 2018;9(16):12695–12704. doi:10.18632/oncotarget.24268.
   PubMedGoogle Scholar
• Ramkissoon LA, Pegram W, Haberberger J, et al. Genomic profiling of circulating tumor DNA from cerebrospinal fluid to guide clinical decision making for patients with primary and metastatic brain tumors. Front Neurol. 2020;11:544680. doi:10.3389/fneur.2020.544680.
   PubMed Web of Science ®Google Scholar
• Huang TY, Piunti A, Lulla RR, et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017;5(1):28. doi:10.1186/s40478-017-0436-6.
   PubMed Web of Science ®Google Scholar
• Sun Y, Li M, Ren S, et al. Exploring genetic alterations in circulating tumor DNA from cerebrospinal fluid of pediatric medulloblastoma. Sci Rep. 2021;11(1):5638. doi:10.1038/s41598-021-85178-6.
   PubMed Web of Science ®Google Scholar
• Connolly ID, Li Y, Pan W, et al. A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma. J Neurooncol. 2017;135(1):29–36. doi:10.1007/s11060-017-2557-y.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. doi:10.1038/ncomms9839.
   PubMed Web of Science ®Google Scholar
• Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016;34(20):2404–2415. doi:10.1200/JCO.2016.66.6487.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094.
   PubMed Web of Science ®Google Scholar
• Kurihara S, Ueda Y, Onitake Y, et al. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors. J Pediatr Surg. 2015;50(12):2094–2097. doi:10.1016/j.jpedsurg.2015.08.033.
   PubMed Web of Science ®Google Scholar
• Liu APY, Northcott PA, Robinson GW, Gajjar A. Circulating tumor DNA profiling for childhood brain tumors: technical challenges and evidence for utility. Lab Invest. 2022;102(2):134–142. doi:10.1038/s41374-021-00719-x.
   PubMed Web of Science ®Google Scholar
• McEwen AE, Leary SES, Lockwood CM. Beyond the blood: CSF-derived cfDNA for diagnosis and characterization of CNS tumors. Front Cell Dev Biol. 2020;8:45. doi:10.3389/fcell.2020.00045.
   PubMed Web of Science ®Google Scholar
• Greuter L, Frank N, Guzman R, Soleman J. The clinical applications of liquid biopsies in pediatric brain tumors: a systematic literature review. Cancers. 2022;14(11):2683. doi:10.3390/cancers14112683.
   PubMed Web of Science ®Google Scholar
• Bruzek AK, Ravi K, Muruganand A, et al. Electronic DNA analysis of CSF cell-free tumor DNA to quantify multi-gene molecular response in pediatric high-grade glioma. Clin Cancer Res. 2020;26(23):6266–6276. doi:10.1158/1078-0432.CCR-20-2066.
   PubMed Web of Science ®Google Scholar
• Miller AM, Szalontay L, Bouvier N, et al. Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult (AYA) brain tumor patients. Neuro-Oncol. 2022;11:noac035. doi:10.1093/neuonc/noac035.
   Google Scholar
• Pagès M, Rotem D, Gydush G, et al. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro Oncol. 2022;24(8):1352–1363. doi:10.1093/neuonc/noab299.
   PubMed Web of Science ®Google Scholar
• Azad TD, Jin MC, Bernhardt LJ, Bettegowda C. Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA. Neurosurg Focus. 2020;48(1):E9. doi:10.3171/2019.9.FOCUS19699.
   PubMed Web of Science ®Google Scholar